A Year in Review: Our Favorite Science Stories from 2018

By Dr. Terry Thomas, STEMCELL Technologies' Chief Scientific Officer

The start of the year often brings new ideas and a fresh outlook for the future. It's also a great time to reflect upon the lessons, successes, and inspirations of the previous year. Looking back on 2018, the fields of stem cell biology, regenerative medicine, and immunotherapy continued to impress and, sometimes, shock the world with advances.

It's difficult to know where to start, but here is a selection of stories from 2018 that our scientists found the most compelling. I hope you enjoy this recap of news from our community. At STEMCELL Technologies, we are always excited to hear about the work you're doing. As Scientists Helping Scientists, we want to support you in any way we can.

Immunotherapy pioneers recognized

  • James P. Allison (MD Anderson Cancer Center) and Tasuku Honjo (Kyoto University) were awarded the 2018 Nobel Prize in Physiology or Medicine. Respectively, these two researchers independently discovered the CTLA-4 and PD-1 pathways for checkpoint inhibition in immune cells, and launched cancer immunotherapy into a new era. Their pioneering work on checkpoint therapy changed the view of how cancer can be managed and has inspired promising new efforts in cancer treatment.

Thought-provoking genome editing news

Genome editing has been one of the biggest science stories of the last five years and continued to dominate the stage in 2018, driving scientific advances in virtually all areas, from basic research to the clinic. Here are just a few of last year’s stories that captured our attention:

  • CRISPR continues to be the focus of genome editing research, and barriers to CRISPR-mediated genome editing of primary cells such as T cells and monocytes are starting to be overcome. These achievements bring us a step closer to engineering immune cells with the specificity necessary in the development of the next generation of immunotherapies.
  • In November, Chinese researcher He Jiankui made the shocking claim that he had used CRISPR gene editing to improve the HIV resistance of twin girls born via IVF. Far from being celebrated, the news sparked an international furore, including concerns about the effects of the gene editing on other systems in the body, the potential risks of off-target effects, and the ethical ramifications of performing germline editing without serious, unmet medical need. The need for caution was underscored by a report from Allan Bradley's group (Wellcome Sanger Institute) in Nature Biotechnology showing that gene editing with CRISPR can cause extensive, unintended genetic changes at both on- and off-target sites. The big question now facing the scientific community, and society at large, is how to build the ethical and regulatory framework necessary to guide if, how, and when human germline editing is performed.
  • Researchers at the Chinese Academy of Sciences, lead by Qi Zhou, Baoyang Hu, and Wei Li, successfully generated bimaternal and bipaternal mice by combining embryonic stem cells and CRISPR-Cas9 technology. The results were published in Cell Stem Cell and have wide-ranging future implications, from furthering our understanding of mammalian reproduction to addressing barriers in same-sex reproduction.
genetically modified T cells

Genome editing of human primary T cells

Learn how to use CRISPR-Cas9 to genetically modify human primary T cells.

Read the Technical Bulletin >

Genome editing of human pluripotent stem cells

Learn how to use CRISPR-Cas9 to genetically modify human pluripotent stem cells.

Read the Technical Bulletin >

Clinical research advancements that caught our eye

  • In a Nature Medicine case study, Steven Rosenberg’s lab at the National Cancer Institute reported successful treatment of a late-stage drug-resistant breast cancer patient with autologous tumor-infiltrating lymphocytes (TILs). Breast cancer treatment has traditionally relied on small molecules/anti-hormone therapy and chemotherapy—this paper represents a shift to immunotherapy approaches.
  • There were several other advances in cancer immunotherapy, including promising preclinical and clinical trials for using CAR-T cells to treat multiple myeloma. Cellectis has several preclinical and clinical trials in place for their “off-the-shelf" universal CAR-T cell (UCART) products for treating various cancers. City of Hope researchers launched a new Phase I trial for CAR T cell treatment of glioblastomas and have several other plans for CAR-T research in various other solid tumors. Progress is also being seen with CAR-NK cell research, including a second Phase I/II clinical trial approved at the University of Texas MD Anderson Cancer Center.
  • Results from a Phase I clinical trial showed promising results for regenerative medicine for retinal diseases. Researchers with The London Project to Cure Blindness reported in Nature Biotech that patients with age-related macular degeneration regained their vision after receiving retinal tissue engineered from human ES and iPS cells.

CAR T cell wallchart

Get a free Nature Protocols wallchart summarizing the CAR T cell manufacturing process.

Request a Copy >

Brief review of CAR T cell research

Explore our selection of key advancements in CAR T cell therapy research.

Read Now >

At the frontier of basic science research

Cerebral organoids webinar

Dr. Madeline Lancaster discusses her groundbreaking work in the development of cerebral organoid technologies.

Watch Now >

Organoid resource center

Explore information on organoid cultures and applications, including webinars, publication lists, researcher profiles, and more.

Go Now >

And a memorable neuroscience finding...

  • The standard theory of memory has been challenged with a report from Dr. David Glanzman’s group at the University of California, Los Angeles that memory of long-term sensitization in snails can be transferred via RNA to untrained snails. The findings support an epigenetic model of memory storage, at least in snails, and raises the (still far-off) possibility of new treatments for memory loss.

If you’re interested in learning about more science that we find inspiring, be sure to visit our Celebration of Science page, where we shine the spotlight on the scientists—and their breakthroughs—that inspire and motivate us.